注射用灯盏花素治疗心绞痛真实世界研究

doi:10.19803/j.1672-8629.2022.08.09

摘要/Abstract

摘要： 目的基于真实世界数据,探究注射用灯盏花素治疗心绞痛时疗效与剂量的相关关系,为该药的临床使用提供参考。方法从全国37家三级甲等医院的医院信息管理系统（HIS）中提取2002年5月20日至2019年11月8日诊断为心绞痛的2 181例患者的诊疗数据。通过SAS 9.2统计软件进行数据整理分析,并以SPSS Clementine12.0对药品疗效及剂量数据的关联情况进行分析。结果 2 181例患者中,老年患者居多,合并疾病以原发性高血压患者数最多。静脉滴注给药3 174例次中超说明书剂量使用2 009例次（63.30%）。合并用药前3位为阿司匹林、美托洛尔、氨氯地平,是治疗冠心病心绞痛常用药。1 569例患者有有效结局指标,药品剂量与疗效间关系分析显示,说明书剂量范围内,治疗剂量为50 mg,患者的治愈率和好转率均更高;超说明书剂量时,治疗剂量为100 mg患者的治愈率和好转率均更高。卡方检验及回归分析显示,对照组治疗心绞痛效果优于注射用灯盏花素。结论临床治疗中应遵循安全用药的原则,在规范指导下合理使用药品。注射用灯盏花素治疗冠心病心绞痛与常规药物联合使用有助于提高临床获益,且注射用灯盏花采用静脉滴注方式给药,剂量50 mg,每日1次疗效更好。

关键词: 注射用灯盏花素, 心绞痛, 真实世界, 量效关系

Abstract: Objective To explore the correlation of therapeutic effect and dosage of Breviscapine injection in the treatment of angina pectoris in the real world so as to provide reference for clinical use. Methods The clinical data on 2 181 patients treated with Breviscapine injection in the treatment of angina pectoris from 37 big hospitals in China between May 20, 2002 and November 8, 2019 was analyzed based on the hospital information system(HIS). The software of SAS 9.2 was used to process data first and SPSS Clementine 21.0 was used to analyze the correlation of therapeutic effect and dosage. Results Among the 2 181 patients, most of them were elderly patients who mostly have comorbidities with essential hypertension. Among the 3 174 cases of intravenous administration, 2 009 cases (63.30%) of the doses beyond the instructions were used. The top three drug combinations were listed in order of frequency: aspirin, metoprolol and amlodipine, which were commonly used drugs for the treatment of angina pectoris. 1 569 patients had effective outcome indicators. Analysis of the relationship between the dosage and therapeutic effect showed that within the range of the prescribed dosage, the cure rate and recovery rate of 50 mg were higher. At the off-label dosage, the cure rate and recovery rate of 100 mg were higher. The results of chi-square test and regression analysis showed that the effect of the control group better than breviscapine injection when dealing with angina pectoris. Conclusion Clinical treatment should adhere to the principle of safe drug use and rational drug use under standardized guidance. The drug combination of Breviscapine injection in the treatment of angina pectoris could help to improve the clinical benefit. It will works better when administered intravenously at a dose of 50 mg once a day.

Key words: Breviscapine injection, angina pectoris, real world, correlation of therapeutic effect and dosage

中图分类号:

R972

张蕾, 黎元元, 谢雁鸣, 王连心, 杨晓晨. 注射用灯盏花素治疗心绞痛真实世界研究[J]. 中国药物警戒, 2022, 19(8): 857-861.

ZHANG Lei, LI Yuanyuan, XIE Yanming, WANG Lianxin, YANG Xiaochen. The medication of Breviscapine injection in the treatment of angina pectoris in the real world[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 857-861.

参考文献

[1] The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases burden in China: an updated summary of 2020[J]. China Circulation Journal(中国循环杂志), 2021, 36(6): 521-545.
[2] Expert Committee on Rational Drug Use of the National Health and Family Planning Commission, China Pharmacists Association. Guidelines for rational drug use of coronary heart disease[J]. Chinese Journal of the Frontiers of Medical Science(Electronic Version)(中国医学前沿杂志(电子版)), 2016, 8(6): 19-108.
[3] SUN YZ, WANG ZY, TANG ZR, et al.Network meta-analysis of Chinese patent medicine of regulating qi and activating blood circulation for angina pectoris[J]. World Chinese Medicine(世界中医药), 2021, 16(21): 3204-3212, 3218.
[4] LI J, WANG J.Etiology and pathogenesis of angina pectoris of coronary heart disease with combination of disease and syndrome[J]. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, 2007, 13(7): 531-533.
[5] LI LJ.Compilation and study of ancient and modern Chinese medicine literature on coronary heart disease and angina Pectoris[D]. Beijing: Beijing University of Chinese Medicine, 2007.
[6] GUO LL, WANG J.Analysis of advantages and distinguishing features about traditional Chinese medicine in prevention and treatment of coronary heart disease[J]. Lishizhen Medicine and Materia Medica Research(时珍国医国药), 2016, 27(10): 2464-2465.
[7] LIN F, WANG J, GUO LL, et al.Composition law of proprietary chinese medicine for coronary heart disease in Chinese Pharmacopoeia[J]. Journal of Traditional Chinese Medicine(中医杂志), 2013, 54(18): 1596-1599.
[8] World Health Organization.International Statistical Classification of Diseases and health-related Problems (10th revision)[疾病和有关健康问题的国际统计分类(第10次修订本)][M]// DONG JW. 2nd ed. Beijing: People’s Medical Publishing House, 2008.
[9] National Standards of People's Republic of China. GB/T 16751.2-1997. TCM Clinical Diagnosis and Treatment Terms-Syndrome Part(中医临床诊疗术语证候部分)[S]. Beijing: Standards Press of China, 1997.
[10] National Pharmacopoeia Committee.Pharmacopoeia of the people's Republic of China(中华人民共和国药典)[M]. Beijing: China Medical Science Press, 2020.
[11] LI XM, SUN SB, JIANG GZ.Research progress on quality control of Breviscapine in injection form[J]. Modern Chinese Medicine(中国现代中药), 2020, 22(6): 971-978.
[12] SU JH, XU H, XU GL.Meta-analysis of effectiveness and safety of breviscapine injection on patients with unstable angina[J]. Journal of Emergency in Traditional Chinese Medicine(中国中医急症), 2019, 28(4): 633-636.
[13] ZHI YJ, ZHAO J, ZHAO H, et al.Efficacy and safety of breviscapine injection in treatment of unstable angina pectoris: systematic review and Meta-analysis[J]. Chinese Journal of Chinese Materia Medica(中国中药杂志), 2018, 43(19): 3940-3955.
[14] ZHANG Y, WANG JF, CAO HY, et al.Efficacy and safety of Dengzhanhuasu and Danshen Injection in treatment of patients with angina pectoris of coronary heart disease: a meta-analysis[J]. Journal of Jilin University(Medicine Edition)(吉林大学学报(医学版)), 2017, 43(2): 317-321.
[15] LI YY, GUO RJ, XIE YM, et al.Expert consensus on injection of Breviscapine in clinical practice[J]. Chinese Journal of Chinese Materia Medica(中国中药杂志), 2020, 45(10): 2296-2299.
[16] XIAO WZ, DAI B, OUYANG LQ, et al.Analysis of 502 cases of off-label of breviscapine for injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(3): 3.
[17] LI J.Analysis of 2047 prescriptions with breviscapin for injection[J]. Capital Medicine(首都食品与医药), 2018, 25(10): 44.
[18] WANG YJ, LI YY, XIE YM, et al.Analysis of the medication characteristics of Breviscapine injection in the real world[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(8): 715-718, 730.
[19] Chinese Community Doctors.Basic principles for the clinical use of TCM injections[J]. Chinese Community Doctors(中国社区医师), 2011, 27(45): 1.
[20] FENG Y, CHEN HY, YAO GT, et al.Meta-analysis of clinical adverse effects of breviscapin for injection[J]. Journal of Shanghai University of Traditional Chinese(上海中医药大学学报), 2016, 30(4): 85-91.
[21] CHENGFENG JM, XIE YM, WANG LX, et al.Analysis of drug characteristics of mailuoshutong pill treating patients with orthopedic and surgical disease in real world[J]. Journal of Traditional Chinese Medicine(中医杂志), 2020, 61(24): 2174-2178.
[22] ZHANG GH, SUN LX, WU XW, et al.Influencing factors of abnormal renal function of breviscapine for injection analyzed via nested case-control study combined with SMOTE algorithm[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(12): 1150-1154.
[23] ZHANG GH, LYU J, WU XW, et al.Effect of breviscapine for injection on liver function in the real world[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 48(5): 6.